GlycoMimetics Announces Executive and Director Changes
Ticker: CBIO · Form: 8-K · Filed: Jan 31, 2025 · CIK: 1253689
| Field | Detail |
|---|---|
| Company | Glycomimetics INC (CBIO) |
| Form Type | 8-K |
| Filed Date | Jan 31, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, executive-compensation, board-of-directors
Related Tickers: GLYC
TL;DR
GlycoMimetics shakes up leadership and exec pay, effective Jan 31.
AI Summary
GlycoMimetics, Inc. announced on January 29, 2025, changes in its executive and director roles. The company filed an 8-K report detailing the departure of certain officers and directors, the election of new directors, and adjustments to compensatory arrangements for key executives. These changes are effective as of January 31, 2025.
Why It Matters
Changes in leadership and executive compensation can signal shifts in company strategy or financial health, impacting investor confidence and stock performance.
Risk Assessment
Risk Level: medium — Executive and director changes, especially without detailed reasons, can introduce uncertainty about the company's future direction and stability.
Key Numbers
- 240-243-1201 — Phone Number (Registrant's principal executive offices)
Key Players & Entities
- GlycoMimetics, Inc. (company) — Registrant
- January 29, 2025 (date) — Date of earliest event reported
- January 31, 2025 (date) — Effective date of changes
- Rockville, MD (location) — Principal executive offices
FAQ
What specific roles were affected by the departures?
The filing indicates the departure of 'certain officers' and 'certain directors' but does not specify the exact roles in this summary.
Were new directors elected?
Yes, the filing explicitly mentions the 'Election of Directors'.
Are there changes to executive compensation?
Yes, the filing notes 'Compensatory Arrangements of Certain Officers' as an item being reported.
What is the effective date of these reported changes?
The earliest event reported is January 29, 2025, and the filing is made as of January 31, 2025, with the date as of change also being January 31, 2025.
Where are GlycoMimetics, Inc.'s principal executive offices located?
The principal executive offices are located at 9708 Medical Center Drive, Rockville, MD 20850.
Filing Stats: 468 words · 2 min read · ~2 pages · Grade level 12.1 · Accepted 2025-01-31 17:00:19
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value GLYC The Nasdaq Stock Mar
Filing Documents
- glyc-20250129x8k.htm (8-K) — 37KB
- 0001558370-25-000576.txt ( ) — 151KB
- glyc-20250129.xsd (EX-101.SCH) — 4KB
- glyc-20250129_lab.xml (EX-101.LAB) — 15KB
- glyc-20250129_pre.xml (EX-101.PRE) — 10KB
- glyc-20250129x8k_htm.xml (XML) — 5KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GLYCOMIMETICS, INC. By: /s/ Brian M. Hahn Date: January 31, 2025 Brian M. Hahn Senior Vice President and Chief Financial Officer 3